US2023111752A1PendingUtilityA1

Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative Recovery

Assignee: ALKAHEST INCPriority: Oct 26, 2018Filed: Dec 6, 2022Published: Apr 13, 2023
Est. expiryOct 26, 2038(~12.3 yrs left)· nominal 20-yr term from priority
A61K 38/38A61K 38/385A61K 9/0026A61P 29/00A61P 25/04A61K 35/16A61K 9/0014A61P 17/02A61P 43/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for improving postoperative recovery are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing conditions associated with postoperative recovery.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method of treating a subject in postoperative recovery, the method comprising administering an effective amount of a Plasma Fraction to the subject. 
     
     
         2 . The method of  claim 1  wherein the Plasma Fraction is a Plasma Protein Fraction. 
     
     
         3 . The method of  claim 2  wherein the Plasma Protein Fraction comprises between 83% to 95% albumin. 
     
     
         4 . The method of  claim 3  wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction. 
     
     
         5 . The method of any of the preceding claims wherein the administering is performed using a Pulse Dose dosing regimen. 
     
     
         6 . A method of treating a subject diagnosed with pain, the method comprising administering an effective amount of a Plasma Fraction to the subject. 
     
     
         7 . The method of  claim 6  wherein the pain is chronic pain. 
     
     
         8 . The method of  claim 6  wherein the pain is peripheral pain. 
     
     
         9 . The method of  claim 6  wherein the pain is central pain. 
     
     
         10 . The method of  claims 6  through  9  wherein the Plasma Fraction is a Plasma Protein Fraction. 
     
     
         11 . The method of  claims 6  through  9  wherein the Plasma Protein Fraction comprises between 83% to 95% albumin. 
     
     
         12 . The method of  claim 11  wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction. 
     
     
         13 . The method of any of  claims 6 - 12  wherein the administering is performed using a Pulse Dose dosing regimen.

Join the waitlist — get patent alerts

Track US2023111752A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.